About the role

Aplyr's Quick Take

This role is for a Senior Director focused on market access strategies in Western Europe for a biotech company. You'll be leading efforts to ensure that the company's therapies reach patients, which involves navigating healthcare systems and regulations. It's a senior-level position, likely requiring significant experience in market access or related fields.

Good fit

Ideal candidates will have extensive experience in market access within the biopharma sector, particularly in Europe. A strategic mindset and strong leadership skills are essential, along with a willingness to challenge the status quo.

Worth noting

The company emphasizes a non-traditional approach to biotech, which may appeal to those looking for an innovative environment. However, the role's specific day-to-day responsibilities are not clearly defined in the posting.

Mavericks Wanted

When was the last time you achieved the impossible? If that thought feels overwhelming, you might want to pause here, but if it sparks excitement...read on
 
In 2015, we pioneered a “moneyball for biotech” approach, pooling projects and promising early-stage research from academia together under one financial umbrella to reduce risk and unleash innovation. This model allows science and small teams of experts to lead the way. We build bridges to groundbreaking advancements in rare disease, and develop life-changing medicines for patients with unmet needs as fast as humanly possible. 
 
Together we define white space, push boundaries, and empower people to solve problems. If you're someone who defies convention, join us and work alongside some of the most respected minds in the industry. Together, we'll ask "why not?" and help reengineer the future of biopharma. At BridgeBio, we value curiosity and experimentation—including the ethical & thoughtful use of AI to improve clarity, speed, and quality of work.

About BridgeBio Pharma, Inc.

BridgeBio is a biopharmaceutical company dedicated to discovering, developing, and delivering transformative medicines for patients living with genetic diseases and genetically defined cancers. Since our founding in 2015, we have built a diverse portfolio of more than 20 drug development programs, ranging from early discovery to late-stage clinical trials, across multiple therapeutic areas including precision oncology, cardiology, endocrinology, neurology, and renal disease. We have already achieved regulatory approval for three therapies and continue to advance promising science from academia into meaningful treatments for patients worldwide.

Who We Are

BridgeBio is a global biotechnology company with our Global Headquarters located in San Francisco, USA, and our International HQ located in Zug, Switzerland. Since establishing our European presence in 2021, we’ve been building empowered, high-performing teams across countries — with experienced colleagues who move quickly, take ownership, and are fuelling the company’s international growth.

At BridgeBio, you’ll find an energetic and collaborative culture where pragmatism meets bold decision-making. We embrace uncertainty with confidence, guided by our commitment to making a meaningful impact for patients. Our people are trusted and empowered, united by urgency, purpose, and the drive to advance science for patients around the world.

To learn more about our story and company culture, visit us at https://bridgebio.com

What You'll Do

This critical role reporting to the regional General Manager - WEU, requires you to be a driven individual with a track record in navigating in the medico-economic environment, securing reimbursement, pricing & patient access to medicines in France (as a priority), Belgium, and the Netherlands. Establish effective collaboration and communication with external stakeholders, such as healthcare

Skills & Tags

go rust ai ios data product design

Aplyr's read

BridgeBio Pharma is a dynamic biotechnology firm dedicated to tackling genetic diseases and cancers, attracting professionals passionate about impactful medical advancements.
Synthesized from recent postings & public sources

What's promising

•BridgeBio focuses on innovative treatments for genetic diseases, offering significant potential for groundbreaking medical advancements.
•The company has a robust pipeline with multiple late-stage clinical trials, indicating strong future growth prospects.
•BridgeBio's strategic partnerships enhance its research capabilities and expand its therapeutic reach.

What to watch

•The company faces high financial risk due to significant R&D expenditures without guaranteed success.
•BridgeBio operates in a highly competitive market with numerous established players.
•Regulatory hurdles for drug approvals can delay product launches and impact revenue.

Why BridgeBio Pharma

•BridgeBio's focus on genetic diseases and cancers sets it apart in the biotechnology sector.
•The company's decentralized model allows for nimble and efficient project management.
•BridgeBio's commitment to rare diseases addresses unmet medical needs, differentiating its mission.

Aplyr’s read is generated by AI from public sources. Was it useful?